Clinical Trials Logo
  1. Home
  2. Contrast-induced Nephropathy
  3. NCT00634491
  4. Details
NCT00634491 Clinical Trial

Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy

Contrast Induced Nephropathy Clinical Trial

Official title:
Effect of Acetazolamide in Prevention of Contrast Nephropathy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00634491
Other study ID # 2438
Secondary ID
Status Completed
Phase Phase 2
First received February 14, 2008
Last updated March 4, 2008
Start date September 2007
Est. completion date February 2008

Study information
Verified date March 2008
Source Shiraz University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is whether Acetazolamide is effective in prevention of contrast nephropathy

Description:

Contrast induced nephropathy is one of common causes of acute renal failure many preventive protocol existed . 240 patient that underwent coronary angiography randomly divided in three groups.Group 1,2,3 will receive Bicarbonate ,Acetazolamide+Normal salin and Normal salin respectively.We compare prevalence of contrast nephropathy in each group.

Recruitment information / eligibility
Status Completed
Enrollment 240
Est. completion date February 2008
Est. primary completion date February 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- patient that underwent coronary angiography

Exclusion Criteria:

- serum Cr. more than 3 mg/dl

- electrolyte and acid-base imbalance

- pulmonary edema

- allergy to Acetazolamide

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Intervention

Drug:
• sodium bicarbonate
150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
• Acetazolamide
Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
• normal salin
1 cc/kg/hr 6 hour before and after angiography

Locations
Country Name City State
Iran, Islamic Republic of Fars Heart Foundation , Kowsar hospital Shiraz

Sponsors (2)
Lead Sponsor Collaborator
Shiraz University of Medical Sciences Fars Heart Foundation

Country where clinical trial is conducted

Iran, Islamic Republic of, 

References & Publications (1)

Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatr Cardiol. 2006 Mar-Apr;27(2):238-42. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Increased base line creatinine at least 25% 24 hr later No
See also
  Status Clinical Trial Phase
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Terminated NCT00476619 - Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial Phase 4
Recruiting NCT03121053 - Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Phase 4
Completed NCT02650336 - Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial N/A
Completed NCT01741896 - Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography? N/A
Terminated NCT00575419 - Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure Phase 1
Not yet recruiting NCT00392405 - Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate Phase 2
Completed NCT00292487 - Patients With Renal Impairment Undergoing CT Phase 4
Recruiting NCT04982419 - Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial Phase 2/Phase 3
Completed NCT00770614 - Hydration and Contrast-Induced Nephropathy in Primary Angioplasty Phase 4
Completed NCT01999517 - Contrast Nephropathy and Nitrates Phase 4
Recruiting NCT00702728 - Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention Phase 3
Completed NCT00639912 - Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction. Phase 4
Completed NCT00531765 - Sodium Bicarbonate in Preventing Contrast Induced Nephropathy N/A
Terminated NCT00494637 - The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy N/A
Completed NCT02516072 - Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy N/A
Active, not recruiting NCT01402232 - REduction of rIsk for Contrast Induced Nephropathy
Recruiting NCT02113540 - Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography Phase 3
Active, not recruiting NCT01456013 - Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients Phase 3
Recruiting NCT01399203 - Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention N/A

External Links